The expected rise in prevalence rates of Alzheimer's disease over the next
several decades has generated a great deal of attention at all levels of so
ciety, including governmental and scientific communities. These concerns ha
ve resulted in a vast number of research studies which have yielded medicat
ions focusing primarily on the symptomatic relief of the cognitive, neurops
ychiatric and behavioral alterations felt to be pathognomic of the disease.
Medical and pharmacological interventions which impact the onset or delay
the progression of the illness are not yet readily available. We review and
discuss the medications which are currently used for the symptomatic treat
ment and management of the disease, as well as discuss new pharmacological
strategies which are under investigation and development.